Thus, targeting the metabolic aberrations in tumor morphogens (CAFs) to reprogram the metabolism in macrophages and modulating the expressions of ARG1, MRC1, and MAPK signaling might lead to the discovery of novel therapeutic strategies [116]. The gene discussed is MRC1; the disease is neoplasm.